U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rachaneni S, McCooty S, Middleton LJ, et al.; on behalf of the Bladder Ultrasound Study (BUS) Collaborative Group. Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Southampton (UK): NIHR Journals Library; 2016 Jan. (Health Technology Assessment, No. 20.7.)

Cover of Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation

Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation.

Show details

References

1.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodynam 2010;29:4–20. 10.3109/9781439807217-111. [PubMed: 19941278] [CrossRef]
2.
Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003;62:28–37. 10.1016/j.urology.2003.09.050. [PubMed: 14662404] [CrossRef]
3.
Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352–60. 10.1111/j.1464-410X.2009.08427.x. [PubMed: 19281467] [CrossRef]
4.
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306–15. 10.1016/j.eururo.2006.09.019. [PubMed: 17049716] [CrossRef]
5.
Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodynam 2013;32:230–7. 10.1002/nau.22295. [PubMed: 22847394] [CrossRef]
6.
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132–8. 10.1111/j.1464-410X.2010.09993.x. [PubMed: 21231991] [CrossRef]
7.
Jimenez-Cidre M, Costa P, Ng-Mak D, Sahai A, Degboe A, Smith CP, et al. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder. Curr Med Res Opin 2014;30:1557–64. 10.1185/03007995.2014.918028. [PubMed: 24762033] [CrossRef]
8.
Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006;97:96–100. 10.1111/j.1464-410X.2005.05889.x. [PubMed: 16336336] [CrossRef]
9.
Jha S, Strelley K, Radley S. Incontinence during intercourse: myths unravelled. Int Urogynecol J 2012;23:633–7. 10.1007/s00192-011-1583-0. [PubMed: 22237785] [CrossRef]
10.
Freeman RM, Adekanmi OA. Overactive bladder. Best Pract Res Clin Obstet Gynaecol 2005;19:829–41. 10.1016/j.bpobgyn.2005.08.002. [PubMed: 16176887] [CrossRef]
11.
Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202–9. 10.1111/j.1464-410X.2008.08036.x. [PubMed: 19278532] [CrossRef]
12.
Mobley DF, Baum N. Etiology, evaluation, and management of nocturia in elderly men and women. Postgrad Med 2014;126:147–53. 10.3810/pgm.2014.03.2751. [PubMed: 24685979] [CrossRef]
13.
Digesu GA, Salvatore S, Fernando R, Khullar V. Mixed urinary symptoms: what are the urodynamic findings? Neurourol Urodynam 2008;27:372–5. 10.1002/nau.20530. [PubMed: 17943988] [CrossRef]
14.
Herzog AR, Diokno AC, Brown MB, Normolle DP, Brock BM. Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults. J Gerontol 1990;45:M67–74. 10.1093/geronj/45.2.M67. [PubMed: 2313045] [CrossRef]
15.
Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 1994;3:291–306. 10.1007/BF00451721. [PubMed: 7841963] [CrossRef]
16.
Brubaker L, Lukacz ES, Burgio K, Zimmern P, Norton P, Leng W, et al. Mixed incontinence: comparing definitions in non-surgical patients. Neurourol Urodyn 2011;30:47–51. 10.1002/nau.20922. [PMC free article: PMC3682677] [PubMed: 21181960] [CrossRef]
17.
Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175:191–4. 10.1016/S0022-5347(05)00067-4. [PubMed: 16406907] [CrossRef]
18.
Andersson KE. Bladder activation: afferent mechanisms. Urology 2002;59:43–50. 10.1016/S0090-4295(01)01637-5. [PubMed: 12007522] [CrossRef]
19.
Kinder RB, Mundy AR. Pathophysiology of idiopathic detrusor instability and detrusor hyper-reflexia. An in vitro study of human detrusor muscle. Br J Urol 1987;60:509–15. 10.1111/j.1464-410X.1987.tb05031.x. [PubMed: 3427334] [CrossRef]
20.
Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50:57–67. 10.1016/S0090-4295(97)00591-8. [PubMed: 9426752] [CrossRef]
21.
Serati M, Salvatore S, Cattoni E, Siesto G, Soligo M, Braga A, et al. Female urinary incontinence at orgasm: a possible marker of a more severe form of detrusor overactivity. Can ultrasound measurement of bladder wall thickness explain it? J Sex Med 2011;8:1710–16. 10.1111/j.1743-6109.2011.02245.x. [PubMed: 21477016] [CrossRef]
22.
Colli E, Artibani W, Goka J, Parazzini F, Wein AJ. Are urodynamic tests useful tools for the initial conservative management of non-neurogenic urinary incontinence? A review of the literature. Eur Urol 2003;43:63–9. 10.1016/S0302-2838(02)00494-3. [PubMed: 12507545] [CrossRef]
23.
Martin JL, Williams KS, Sutton AJ, Abrams KR, Assassa RP. Systematic review and meta-analysis of methods of diagnostic assessment for urinary incontinence. Neurourol Urodynam 2006;25:674–83. 10.1002/nau.20340. [PubMed: 17016795] [CrossRef]
24.
Jackson SL. Prevalence and natural history of female incontinence. J Womens Health 1998;7:472–3. [PubMed: 9611707]
25.
James M, Jackson S, Shepherd A, Abrahms P. Pure stress leakage symptomatology: is it safe to discount detrusor instability? Br J Obstet Gynaecol 1999;106:1255–8. 10.1111/j.1471-0528.1999.tb08178.x. [PubMed: 10609718] [CrossRef]
26.
Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int 2009;103:24–32. 10.1111/j.1464-410X.2009.08438.x. [PubMed: 19302499] [CrossRef]
27.
Parsons M, Amundsen CL, Cardozo L, Vella M, Webster GD, Coats AC, et al. Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence. Neurourol Urodynam 2007;26:800–6. 10.1002/nau.20406. [PubMed: 17335054] [CrossRef]
28.
Chung SD, Chui B, Kuo HC, Chuang YC, Wang CC, Guan Z, et al. Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int 2010;5:668–72. 10.1002/nau.21057. [PubMed: 19793377] [CrossRef]
29.
Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003;22:105–8. 10.1002/nau.10099. [PubMed: 12579626] [CrossRef]
30.
Department of Health. NHS Reference Costs 2012–13. London: Department of Health; 2013.
31.
Health and Social Care Information Centre. Hospital Outpatient Activity 2013–14. London: Health and Social Care Information Centre; 2014.
32.
Public Health England. The NHS Atlas of Variation in Diagnostic Services. London: Public Health England; 2013.
33.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5–26. 10.1007/s00192-009-0976-9. [PubMed: 19937315] [CrossRef]
34.
Digesu GA, Hutchings A, Salvatore S, Selvaggi L, Khullar V. Reproducibility and reliability of pressure flow parameters in women. BJOG 2003;110:774–6. 10.1111/j.1471-0528.2003.02081.x. [PubMed: 12892691] [CrossRef]
35.
Digesu GA, Khullar V, Panayi D, Calandrini M, Gannon M, Nicolini U. Should we explain lower urinary tract symptoms to patients? Neurourol Urodyn 2008;27:368–71. 10.1002/nau.20527. [PubMed: 17943984] [CrossRef]
36.
NICE. Urinary Incontinence In Women. Clinical Guideline Cg171. London: NICE; 2013.
37.
Pacheco-Unguetti AP, Acosta A, Callejas A, Lupianez J. Attention and anxiety: different attentional functioning under state and trait anxiety. Psychol Sci 2010;21:298–304. 10.1177/0956797609359624. [PubMed: 20424060] [CrossRef]
38.
Ku JH, Kim SW, Kim HH, Paick JS, Son H, Oh SJ. Patient experience with a urodynamic study: a prospective study in 208 patients. J Urology 2004;171:2307–10. 10.1097/01.ju.0000125144.82338.0c. [PubMed: 15126810] [CrossRef]
39.
Shaw C, Williams K, Assassa PR, Jackson C. Patient satisfaction with urodynamics: a qualitative study. J Adv Nurs 2000;32:1356–63. 10.1046/j.1365-2648.2000.01627.x. [PubMed: 11136403] [CrossRef]
40.
Shaw C, Williams KS, Assassa RP. Patients’ views of a new nurse-led continence service. J Clin Nurs 2000;9:574–82. 10.1046/j.1365-2702.2000.00414.x. [PubMed: 11261138] [CrossRef]
41.
Yeung JY, Eschenbacher MA, Pauls RN. Pain and embarrassment associated with urodynamic testing in women. Int Urogynecol J 2014;25:645–50. 10.1007/s00192-013-2261-1. [PubMed: 24280994] [CrossRef]
42.
Cartwright R, Afshan I, Derpapas A, Vijaya G, Khullar V. Novel biomarkers for overactive bladder. Nat Rev Urol 2011;8:139–45. 10.1038/nrurol.2011.7. [PubMed: 21321572] [CrossRef]
43.
Oelke M. International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: the need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophy. Neurourol Urodyn 2010;29:634–9. 10.1002/nau.20834. [PubMed: 20432327] [CrossRef]
44.
Khullar V, Salvatore S, Cardozo L, Bourne TH, Abbott D, Kelleher C. A novel technique for measuring bladder wall thickness in women using transvaginal ultrasound. Ultrasound Obst Gynecol 1994;4:220–3. 10.1046/j.1469-0705.1994.04030220.x. [PubMed: 12797185] [CrossRef]
45.
Elbadawi A, Diokno AC, Millard RJ. The aging bladder: morphology and urodynamics. World J Urol 1998;16:S10–34. 10.1007/PL00014134. [PubMed: 9775413] [CrossRef]
46.
Hakenberg OW, Linne C, Manseck A, Wirth MP. Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn 2000;19:585–93. 10.1002/1520-6777(2000)19:5<585::AID-NAU5>3.0.CO;2-U. [PubMed: 11002301] [CrossRef]
47.
Kuhn A, Bank S, Robinson D, Klimek M, Kuhn P, Raio L. How should bladder wall thickness be measured? A comparison of vaginal, perineal and abdominal ultrasound. Neurourol Urodyn 2010;29:1393–6. 10.1002/nau.20876. [PubMed: 20976813] [CrossRef]
48.
Latthe PM, Champaneria R, Khan KS. Systematic review of the accuracy of ultrasound as the method of measuring bladder wall thickness in the diagnosis of detrusor overactivity. Int Urogynecol J 2010;21:1019–24. 10.1007/s00192-010-1144-y. [PubMed: 20424825] [CrossRef]
49.
Khullar V, Cardozo LD, Salvatore S, Hill S. Ultrasound: a noninvasive screening test for detrusor instability. Br J Obstet Gynaecol 1996;103:904–8. 10.1111/j.1471-0528.1996.tb09910.x. [PubMed: 8813311] [CrossRef]
50.
Minardi D, Piloni V, Amadi A, El Asmar Z, Milanese G, Muzzonigro G. Correlation between urodynamics and perineal ultrasound in female patients with urinary incontinence. Neurourol Urodyn 2007;26:176–82. 10.1002/nau.20327. [PubMed: 17016799] [CrossRef]
51.
Lekskulchai O, Dietz HP. Detrusor wall thickness as a test for detrusor overactivity in women. Ultrasound Obstet Gynecol 2008;32:535–9. 10.1002/uog.5370. [PubMed: 18634113] [CrossRef]
52.
Robinson D, Anders K, Cardozo L, Bidmead J, Toozs-Hoson P, Khullar V. Can ultrasound replace ambulatory urodynamics when investigating women with irritative urinary symptoms? BJOG 2002;109:145–8. 10.1111/j.1471-0528.2002.01021.x. [PubMed: 11888096] [CrossRef]
53.
Yang JM, Huang WC. Bladder wall thickness on ultrasonographic cystourethrography: affecting factors and their implications. J Ultrasound Med 2003;22:777–82. [PubMed: 12901404]
54.
Kuhn A, Genoud S, Robinson D, Herrmann G, Gunthert A, Brandner S, et al. Sonographic transvaginal bladder wall thickness: does the measurement discriminate between urodynamic diagnoses? Neurourol Urodyn 2011;30:325–8. 10.1002/nau.20997. [PubMed: 20949598] [CrossRef]
55.
Ibrahim S, Najdy M. Measuring Bladder Wall Thickness in Cases of Detrusor Instability Using Transvaginal Ultrasound. Proceedings of the International Continence Society (ICS) 2011 Annual Meeting: Glasgow; 2011.
56.
Kuo HC. Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography. Int Urogynecol J 2009;20:1293–9. 10.1007/s00192-009-0946-2. [PubMed: 19557300] [CrossRef]
57.
Ozturk H, Aydur E, Irkilata HC, Seckin B, Dayanc M. The Diagnostic Role of Transabdominal Ultrasonographic Bladder Wall Thickness in Female Urinary Incontinence. Glasgow: Proceedings of the International Continence Society (ICS) 2011 Annual Meeting; 2011. 10.1016/j.urology.2011.07.1250. [CrossRef]
58.
Soligo M, Salvatore S, Khullar V, Luppino G, Arcari V, Milani R. Overactive Bladder Definition and Ultrasound Measurement of Bladder Wall Thickness: The Right Way Without Urodynamics. Heidelberg: Proceedings of the International Continence Society (ICS) 2002 Annual Meeting; 2002.
59.
Yang JM, Huang WC. Discrimination of bladder disorders in female lower urinary tract symptoms on ultrasonographic cystourethrography. J Ultrasound Med 2002;21:1249–55. [PubMed: 12418766]
60.
Clement S, Candy B, Heath V, To M, Nicolaides KH. Transvaginal ultrasound in pregnancy: its acceptability to women and maternal psychological morbidity. Ultrasound Obstet Gynecol 2003;22:508–14. 10.1002/uog.893. [PubMed: 14618665] [CrossRef]
61.
Nager CW, Brubaker L, Litman HJ, Zyczynski HM, Varner RE, Amundsen C, et al. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med 2012;366:1987–97. 10.1056/NEJMoa1113595. [PMC free article: PMC3386296] [PubMed: 22551104] [CrossRef]
62.
Van Leijsen S, Kluivers K, Mol B, Broekhuis S, Milani A, Bongers M, et al. Can preoperative urodynamic investigation be omitted in women with stress urinary incontinence? A non-inferiority randomized controlled trial. Neurourol Urodyn 2012;31:1118–23. 10.1002/nau.22230. [PubMed: 22488817] [CrossRef]
63.
van Leijsen SAL, Kluivers KB, Mol BWJ, Milani AL, Roovers J-PW, den Boon J, et al. Value of urodynamics before stress urinary incontinence surgery: a randomized controlled trial. Obstet Gynecol 2013;121:999–1008. 10.1097/AOG.0b013e31828c68e3. [PubMed: 23635736] [CrossRef]
64.
Weber A, Taylor R, Wei J, Lemack G, Piedmonte M, Walters M. The cost-effectiveness of preoperative testing (basic office assessment vs urodynamics) for stress urinary incontinence in women. BJU Int 2002;89:356–63. 10.1046/j.1464-4096.2001.01687.x. [PubMed: 11872024] [CrossRef]
65.
Geisler JP, Drenchko R. Cost-effectiveness of urodynamics testing in women with predominant stress incontinence symptoms. Obstet Gynecol 2014;123:197S. 10.1097/01.AOG.0000447227.13819.5d. [CrossRef]
66.
Bosch J, Cardozo L, Hashim H, Hilton P, Oelke M, Robinson D. Constructing trials to show whether urodynamic studies are necessary in lower urinary tract dysfunction. Neurourol Urodyn 2011;30:735–40. 10.1002/nau.21130. [PubMed: 21661022] [CrossRef]
67.
Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004;23:322–30. 10.1002/nau.20041. [PubMed: 15227649] [CrossRef]
68.
Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM. Evidence of bias and variation in diagnostic accuracy studies. CMAJ 2006;174:469–76. 10.1503/cmaj.050090. [PMC free article: PMC1373751] [PubMed: 16477057] [CrossRef]
69.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41–4. 10.1136/bmj.326.7379.41. [PMC free article: PMC1124931] [PubMed: 12511463] [CrossRef]
70.
Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189–202. 10.7326/0003-4819-140-3-200402030-00010. [PubMed: 14757617] [CrossRef]
71.
Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11:88–94. 10.1177/0272989X9101100203. [PubMed: 1907710] [CrossRef]
72.
Panayi DC, Digesu GA, Tekkis P, Fernando R, Khullar V. Ultrasound measurement of vaginal wall thickness: a novel and reliable technique. Int Urogynecol J 2010;21:1265–70. 10.1007/s00192-010-1183-4. [PubMed: 20502876] [CrossRef]
73.
Lang EV, Benotsch EG, Fick LJ, Lutgendorf S, Berbaum ML, Berbaum KS, et al. Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 2000;355:1486–90. 10.1016/S0140-6736(00)02162-0. [PubMed: 10801169] [CrossRef]
74.
Lang EV, Hatsiopoulou O, Koch T, Berbaum K, Lutgendorf S, Kettenmann E, et al. Can words hurt? Patient–provider interactions during invasive procedures. Pain 2005;114:303–9. 10.1016/j.pain.2004.12.028. [PubMed: 15733657] [CrossRef]
75.
Barlow DH. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. 2nd edn. New York, NY: Guilford Press; 2001.
76.
Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801–10. 10.1046/j.1464-410x.1998.00717.x. [PubMed: 9666761] [CrossRef]
77.
Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. JAMA 1982;248:1194–8. 10.1001/jama.1982.03330100032026. [PubMed: 7109138] [CrossRef]
78.
Ouslander JG, Sier HC. Drug therapy for geriatric urinary incontinence. Clin Geriatr Med 1986;2:789–807. [PubMed: 3536063]
79.
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJC. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429. 10.1002/14651858.cd005429.pub2. [PubMed: 22258963] [CrossRef]
80.
Tincello DG, Rashid T, Revicky V. Emerging treatments for overactive bladder: clinical potential of botulinum toxins. Res Rep Urol 2014;6:51–7. 10.2147/rru.s44665. [PMC free article: PMC4039398] [PubMed: 24892033] [CrossRef]
81.
Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology 2013;81:491–7. 10.1016/j.urology.2012.11.010. [PubMed: 23290144] [CrossRef]
82.
Burton C, Sajja A, Latthe P. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn 2012;31:1206–16. 10.1002/nau.22251. [PubMed: 22581511] [CrossRef]
83.
Smith A, Bevan D, Douglas HR, James D. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ 2013;347:f5170. 10.1136/bmj.f5170. [PubMed: 24021756] [CrossRef]
84.
Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009;103:931–7. 10.1111/j.1464-410X.2009.08361.x. [PubMed: 19281469] [CrossRef]
85.
Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, van Kerrebroeck PE, Hassouna MM, Gajewski JB, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 2008;101:325–9. 10.1111/j.1464-410X.2007.07258.x. [PubMed: 18070199] [CrossRef]
86.
Rovner ES, Goudelocke CM. Urodynamics in the evaluation of overactive bladder. Curr Urol Rep 2010;11:343–7. 10.1007/s11934-010-0130-8. [PubMed: 20585906] [CrossRef]
87.
Vandoninck V, van Balken MR, Finazzi Agro E, Petta F, Micali F, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn 2003;22:227–32. 10.1002/nau.10111. [PubMed: 12707873] [CrossRef]
88.
Rachaneni S, Latthe P. Does preoperative urodynamics improve outcomes for women undergoing surgery for stress urinary incontinence? A systematic review and meta-analysis. BJOG 2015;122:8–16. 10.1111/1471-0528.12954. [PubMed: 25041381] [CrossRef]
89.
Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006;175:835–41. 10.1016/S0022-5347(05)00326-5. [PubMed: 16469561] [CrossRef]
90.
Weber AM, Walters MD. Cost-effectiveness of urodynamic testing before surgery for women with pelvic organ prolapse and stress urinary incontinence. Am J Obstet Gynecol 2000;183:1338–47. 10.1067/mob.2000.111251. [PubMed: 11120494] [CrossRef]
91.
Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62:507–14. 10.1016/j.eururo.2011.12.056. [PubMed: 22236796] [CrossRef]
92.
Curtis L. Unit Costs of Health and Social Care 2013. University of Kent, Canterbury: Personal Social Services Research Unit; 2013.
93.
Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996;175:10–7. 10.1016/S0002-9378(96)70243-0. [PubMed: 8694033] [CrossRef]
94.
Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005;43(Suppl. 7):5–14. 10.1097/01.mlr.0000170001.10393.b7. [PubMed: 16056003] [CrossRef]
95.
Rachaneni S, Balogun M, Latthe P. Bladder-wall-thickness ultrasound scan in the investigation of LUTS in women: challenges and limitations. Int Urogynecol J 2013;24:725–8. 10.1007/s00192-013-2048-4. [PubMed: 23376906] [CrossRef]
96.
Schafer W, Abrams P, Liao LM, Mattiasson A, Pesce F, Spangberg A, et al. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261–74. 10.1002/nau.10066. [PubMed: 11948720] [CrossRef]
97.
Khullar V, Salvatore S, Cardozo L, Bourne TH, Abbott D, Kelleher C. A novel technique for measuring bladder wall thickness in women using transvaginal ultrasound. Ultrasound Obstet Gynecol 1994;4:220–3. 10.1046/j.1469-0705.1994.04030220.x. [PubMed: 12797185] [CrossRef]
98.
Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004;329:168–9. 10.1136/bmj.329.7458.168. [PMC free article: PMC478236] [PubMed: 15258077] [CrossRef]
99.
Xiao-Hua Z, Obuchowski NA, McClish DK. Statistical Methods in Diagnostic Medicine. 2nd edn. Hoboken, NJ: Wiley; 2011.
100.
Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press; 2004.
101.
Schafer JL. Analysis of Incomplete Multivariate Data. London: Chapman & Hall; 1997. 10.1201/9781439821862. [CrossRef]
102.
Hashim H, Abrams P. Pharmacological management of women with mixed urinary incontinence. Drugs 2006;66:591–606. 10.2165/00003495-200666050-00002. [PubMed: 16620139] [CrossRef]
103.
Foon R, Toozs-Hobson P, Latthe P. Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies. Cochrane Database Syst Rev 2012;10:CD008224. 10.1002/14651858.cd008224.pub2. [PubMed: 23076941] [CrossRef]
104.
Nager CW, Albo ME, FitzGerald MP, McDermott SM, Kraus S, Richter HE, et al. Process for development of multicenter urodynamic studies. Urology 2007;69:63–7. 10.1016/j.urology.2006.08.1118. [PMC free article: PMC1855147] [PubMed: 17270617] [CrossRef]
105.
Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JHP, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061–6. 10.1001/jama.282.11.1061. [PubMed: 10493205] [CrossRef]
106.
Broekhuis SR, Kluivers KB, Hendriks JCM, Massolt ET, Groen J, Vierhout ME. Reproducibility of same session repeated cystometry and pressure-flow studies in women with symptoms of urinary incontinence. Neurourol Urodyn 2010;29:428–31. 10.1002/nau.20783. [PubMed: 19618451] [CrossRef]
107.
Homma Y, Kondo Y, Takahashi S, Kitamura T, Kawabe K. Reproducibility of cystometry in overactive detrusor. Eur Urol 2000;38:681–5. 10.1159/000020362. [PubMed: 11111184] [CrossRef]
108.
Mortensen S, Lose G, Thyssen H. Repeatability of cystometry and pressure-flow parameters in female patients. Int Urogynecol J Pelvic Floor Dysfunct 2002;13:72–5. 10.1007/s001920200018. [PubMed: 12054185] [CrossRef]
109.
Sorensen SS, Nielsen JB, Norgaard JP, Knudsen LM, Djurhuus JC. Changes in bladder volumes with repetition of water cystometry. Urol Res 1984;12:205–8. 10.1007/BF00256804. [PubMed: 6495446] [CrossRef]
110.
Brostrom S, Jennum P, Lose G. Short-term reproducibility of cystometry and pressure-flow micturition studies in healthy women. Neurourol Urodyn 2002;21:457–60. 10.1002/nau.10019. [PubMed: 12232880] [CrossRef]
111.
Bellucci CH, Wollner J, Gregorini F, Birnbock D, Kozomara M, Mehnert U, et al. Neurogenic lower urinary tract dysfunction – do we need same session repeat urodynamic investigations? J Urol 2012;187:1318–23. 10.1016/j.juro.2011.11.107. [PubMed: 22341264] [CrossRef]
112.
Gupta A, Defreitas G, Lemack GE. The reproducibility of urodynamic findings in healthy female volunteers: results of repeated studies in the same setting and after short-term follow-up. Neurourol Urodyn 2004;23:311–16. 10.1002/nau.20039. [PubMed: 15227647] [CrossRef]
113.
Serati M, Salvatore S, Cattoni E, Soligo M, Cromi A, Ghezzi F. Ultrasound measurement of bladder wall thickness in different forms of detrusor overactivity. Int Urogynecol J 2010;21:1405–11. 10.1007/s00192-010-1194-1. [PubMed: 20535449] [CrossRef]
114.
Chan L, The S, Titus J, Tse V. P14.02: The value of bladder wall thickness measurement in the assessment of overactive bladder syndrome. Ultrasound Obstet Gynecol 2005;26:460. 10.1002/uog.2546. [CrossRef]
115.
Parsons M, Vella M, Cardozo L. Does Bladder Wall Thickness Discriminate Detrusor Overactivity From Overactive Bladder and Normality. Montreal: Proceedings of the International Continence Society (ICS) 2002 Annual Meeting; 2005.
116.
Blatt AH, Titus J, Chan L. Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction. J Urol 2008;179:2275–8. 10.1016/j.juro.2008.01.118. [PubMed: 18423703] [CrossRef]
117.
Abou-Gamrah A, Fawzy M, Sammour H, Tadros S. Ultrasound assessment of bladder wall thickness as a screening test for detrusor instability. Arch Gynecol Obstet 2014;289:1023–8. 10.1007/s00404-013-3092-5. [PubMed: 24276424] [CrossRef]
118.
Otsuki EN, Araujo Junior E, Oliveira E, Sartori MG, Girao MJ, Jarmy-Di Bella ZI. Ultrasound thickness of bladder wall in continent and incontinent women and its correlation with cystometry. Sci World J 2014;2014:684671. 10.1155/2014/684671. [PMC free article: PMC4236895] [PubMed: 25538959] [CrossRef]
119.
Silva JA, Gonsalves Mde C, de Melo RT, Carrerette FB, Damiao R. Association between the bladder wall thickness and urodynamic findings in patients with spinal cord injury. World J Urol 2015;33:131–5. 10.1007/s00345-014-1265-x. [PubMed: 24573904] [CrossRef]
120.
van der Schouw YT, Verbeek AL, Ruijs SH. Guidelines for the assessment of new diagnostic tests. Invest Radiol 1995;30:334–40. 10.1097/00004424-199506000-00002. [PubMed: 7490184] [CrossRef]
121.
Ulmsten U, Falconer C. Connective tissue in female urinary incontinence. Curr Opin Obstet Gynecol 1999;11:509–15. 10.1097/00001703-199910000-00017. [PubMed: 10526931] [CrossRef]
122.
Salvatore S, Serati M, Digesu GA, Triacca P, Uccella S, Khullar V, et al. Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:701–4. 10.1007/s00192-007-0512-8. [PubMed: 18066482] [CrossRef]
123.
Rovner ES. Complications of anterior compartment vaginal surgery. Curr Urol Rep 2007;8:405–12. 10.1007/s11934-007-0039-z. [PubMed: 17880841] [CrossRef]
124.
Vandoninck V, Van Balken MR, Finazzi Agro E, Petta F, Caltagirone C, Heesakkers JP, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn 2003;22:17–23. 10.1002/nau.10036. [PubMed: 12478596] [CrossRef]
125.
South MM, Romero AA, Jamison MG, Webster GD, Amundsen CL. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:1395–8. 10.1007/s00192-007-0351-7. [PubMed: 17364132] [CrossRef]
126.
Kraus SR, Dmochowski R, Albo ME, Xu L, Klise SR, Roehrborn CG. Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourol Urodyn 2010;29:741–7. 10.1002/nau.20825. [PubMed: 20151469] [CrossRef]
127.
Al-Hayek S, Belal M, Abrams P. Does the patient’s position influence the detection of detrusor overactivity? Neurourol Urodyn 2008;27:279–86. 10.1002/nau.20503. [PubMed: 17724734] [CrossRef]
128.
Arunkalaivanan AS, Mahomoud S, Howell M. Does posture affect cystometric parameters and diagnoses? Int Urogynecol J Pelvic Floor Dysfunct 2004;15:422–4; discussion 4. 10.1007/s00192-004-1195-z. [PubMed: 15549262] [CrossRef]
129.
Tubaro A, Khullar V, Oelke M, Wijkstra H, Tretter R, Stow B, et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the shrink study. Neurourol Urodyn 2013;32:711–12.
130.
Amer SAKS, Li TC, Bygrave C, Sprigg A, Saravelos H, Cooke ID. An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries. Hum Reprod 2002;17:1616–22. 10.1093/humrep/17.6.1616. [PubMed: 12042287] [CrossRef]
131.
Price DD, Mcgrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:45–56. 10.1016/0304-3959(83)90126-4. [PubMed: 6226917] [CrossRef]
132.
Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992;31:301–6. 10.1111/j.2044-8260.1992.tb00997.x. [PubMed: 1393159] [CrossRef]
133.
Agresti A. Score and pseudo-score confidence intervals for categorical data analysis. Stat Biopharm Res 2011;3:163–72. 10.1198/sbr.2010.09053. [CrossRef]
134.
Gorton E, Stanton S. Women’s attitudes to urodynamics: a questionnaire survey. Br J Obstet Gynaecol 1999;106:851–6. 10.1111/j.1471-0528.1999.tb08408.x. [PubMed: 10453837] [CrossRef]
135.
Arntz A, Vaneck M, Heijmans M. Predictions of dental pain – the fear of any expected evil, is worse than the evil itself. Behav Res Ther 1990;28:29–41. 10.1016/0005-7967(90)90052-K. [PubMed: 2302147] [CrossRef]
136.
Terry R, Brodie EE, Niven CA. Exploring the phenomenology of memory for pain: Is previously experienced acute pain consciously remembered or simply known? J Pain 2007;8:467–75. 10.1016/j.jpain.2006.12.006. [PubMed: 17306627] [CrossRef]
137.
Bradley P, Kennedy Y. Confronting pain face-to-face at NSU. Todays FDA 2008;20:37–40. [PubMed: 19266691]
138.
McNeil DW, Berryman ML. Components of dental fear in adults? Behav Res Ther 1989;27:233–6. 10.1016/0005-7967(89)90041-7. [PubMed: 2730504] [CrossRef]
139.
Denberg TD, Melhado TV, Coombes JM, Beaty BL, Berman K, Byers TE, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med 2005;20:989–95. 10.1111/j.1525-1497.2005.00164.x. [PMC free article: PMC1490266] [PubMed: 16307622] [CrossRef]
140.
Yiou R, Audureau E, Loche CM, Dussaud M, Lingombet O, Binhas M. Comprehensive evaluation of embarrassment and pain associated with invasive urodynamics. Neurourol Urodyn 2015;34:156–60. 10.1002/nau.22521. [PubMed: 24259301] [CrossRef]
141.
Neustaedter EG, Milne J, Shorten K, Weckman B, Tse A, Tange S. How well informed are women who undergo urodynamic testing? Neurourol Urodynam 2011;30:572–7. 10.1002/nau.21014. [PubMed: 21268100] [CrossRef]
142.
Spielberger CDC. Manual for the State-Trait Anxiety Inventory (Form Y). Menlo Park, CA: Mind Garden Inc.; 1983.
143.
Perry S, McGrother CW, Turner K. An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model. Br J Health Psychol 2006;11:463–82. 10.1348/135910705X60742. [PubMed: 16870056] [CrossRef]
144.
Tinetti ME, Inouye SK, Gill TM, Doucette JT. Shared risk-factors for falls, incontinence, and functional dependence – unifying the approach to geriatric syndromes. JAMA 1995;273:1348–53. 10.1001/jama.1995.03520410042024. [PubMed: 7715059] [CrossRef]
145.
Heidrich SM, Wells TJ. Effects of urinary incontinence: psychological well-being and distress in older community-dwelling women. J Gerontol Nurs 2004;30:47–54. 10.3928/0098-9134-20040501-10. [PubMed: 15152744] [CrossRef]
146.
Saleem A. In women with urinary incontinence how necessary is cystometry? J Pak Med Assoc 2010;60:356–9. [PubMed: 20527606]
147.
Lemeshow H. Applied Logistic Regression. 2nd edn. New York, NY: John Wiley and Sons, Inc. 2000.
148.
Verbeke G MG. Linear Mixed Models For Longitudinal Data. New York, NY: Springer; 2000.
149.
Jackson S. The patient with an overactive bladder--symptoms and quality-of-life issues. Urology 1997;50(Suppl. 6A):18–22; discussion 3–4. 10.1016/S0090-4295(97)00580-3. [PubMed: 9426747] [CrossRef]
150.
Martin J, Williams K, Abrams KR, Turner DA, Sutton AJ, Chapple C, et al. Systematic review and evaluation of methods of assessing urinary incontinence. Neurourol Urodyn 2006;25:674–83. 10.1002/nau.20340. [PubMed: 17016795] [CrossRef]
151.
Clement KD, Lapitan MC, Omar MI, Glazener CM. Urodynamic studies for management of urinary incontinence in children and adults: A short version Cochrane systematic review and meta-analysis. Neurourol Urodyn 2015;34:407–12. 10.1002/nau.22584. [PubMed: 24853652] [CrossRef]
152.
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92. 10.1097/01.MLR.0000062554.74615.4C. [PubMed: 12719681] [CrossRef]
153.
McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol 2007;7:30. 10.1186/1471-2288-7-30. [PMC free article: PMC1936999] [PubMed: 17608932] [CrossRef]
154.
Majumdar A, Latthe P, Toozs-Hobson P. Urodynamics prior to treatment as an intervention: a pilot study. Neurourol Urodyn 2010;29:522–6. 10.1002/nau.20810. [PubMed: 19731310] [CrossRef]
155.
Nager CW, Brubaker L, Daneshgari F, Litman HJ, Dandreo KJ, Sirls L, et al. Design of the Value of Urodynamic Evaluation (ValUE) trial: a non-inferiority randomized trial of preoperative urodynamic investigations. Contemp Clin Trials 2009;30:531–9. 10.1016/j.cct.2009.07.001. [PMC free article: PMC3057197] [PubMed: 19635587] [CrossRef]
156.
Gotoh M, Homma Y, Yokoyama O, Nishizawa O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology 2011;78:768–73. 10.1016/j.urology.2011.06.020. [PubMed: 21855969] [CrossRef]
157.
Department of Health. The Handbook to the NHS Constitution (2012 edition). London: Department of Health; 2012.
158.
Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012;61:834–9. 10.1016/j.eururo.2011.12.011. [PubMed: 22204745] [CrossRef]
159.
Jorgensen L, Lose G, Mortensen SO, Pedersen LM, Kristensen JK. The Burch colposuspension for urinary incontinence in patients with stable and unstable detrusor function. Neurourol Urodyn 1988;7:435–41. 10.1002/nau.1930070504. [CrossRef]
160.
Latthe PM, Foon R, Toozs-Hobson P. Transobturator and retropubic tape procedures in stress urinary incontinence: a systematic review and meta-analysis of effectiveness and complications. BJOG 2007;114:522–31. 10.1111/j.1471-0528.2007.01268.x. [PubMed: 17362484] [CrossRef]
161.
Jain P, Jirschele K, Botros SM, Latthe PM. Effectiveness of midurethral slings in mixed urinary incontinence: a systematic review and meta-analysis. Int Urogynecol J 2011;22:923–32. 10.1007/s00192-011-1406-3. [PubMed: 21455757] [CrossRef]
162.
Dean N, Herbison P, Ellis G, Wilson D. Laparoscopic colposuspension and tension-free vaginal tape: a systematic review. BJOG 2006;113:1345–53. 10.1111/j.1471-0528.2006.01101.x. [PubMed: 17176277] [CrossRef]
163.
Kulseng-Hanssen S, Berild GH. Subjective and objective incontinence 5 to 10 years after Burch colposuspension. Neurourol Urodyn 2002;21:100–5. 10.1002/nau.10011. [PubMed: 11857661] [CrossRef]
164.
Novara G, Artibani W, Barber MD, Chapple CR, Costantini E, Ficarra V, et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol 2010;58:218–38. 10.1016/j.eururo.2010.04.022. [PubMed: 20434257] [CrossRef]
165.
Leal J, Wordsworth S, Legood R, Blair E. Eliciting expert opinion for economic models: an applied example. Value Health 2007;10:195–203. 10.1111/j.1524-4733.2007.00169.x. [PubMed: 17532812] [CrossRef]
166.
Siddiqui NY, Wu JM, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review. Neurourol Urodyn 2010;29(Suppl. 1):18–23. 10.1002/nau.20786. [PubMed: 20419795] [CrossRef]
167.
Tufts Medical Center. Cost-Effectiveness Analysis Registry. URL https://research​.tufts-nemc.org/cear4/ (accessed June 2014).
168.
Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. J Urol 2012;187:178–84. 10.1016/j.juro.2011.09.052. [PubMed: 22100006] [CrossRef]
169.
Wu JM, Fulton RG, Amundsen CL, Knight SK, Kuppermann M. Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg 2011;17:184–9. 10.1097/SPV.0b013e318223c8ad. [PubMed: 22453849] [CrossRef]
170.
Arlandis-Guzman S, Errando-Smet C, Trocio J, Arumi D, Rejas J. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model. BMC Urol 2011;11:9. 10.1186/1471-2490-11-9. [PMC free article: PMC3126790] [PubMed: 21599928] [CrossRef]
171.
Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 2010;106:506–14. 10.1111/j.1464-410X.2009.09160.x. [PubMed: 20132203] [CrossRef]
172.
Hakkaart L, Verboom P, Phillips R, Al MJ. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009;41:293–8. 10.1007/s11255-008-9448-2. [PubMed: 18704742] [CrossRef]
173.
Herschorn S, Vicente C, Piwko C. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. J Med Econ 2010;13:508–15. 10.3111/13696998.2010.509244. [PubMed: 20690893] [CrossRef]
174.
Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: A Markov model. Neurourol Urodyn 1998;17:599–611. 10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J. [PubMed: 9829424] [CrossRef]
175.
Pradelli L, Iannazzo S. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. J Med Econ 2009;12:25–35. 10.3111/13696990902767800. [PubMed: 19450062] [CrossRef]
176.
Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A cost–utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24:2173–9. 10.1185/03007990802234829. [PubMed: 18565239] [CrossRef]
177.
Dumville J, Manca A, Kitchener H, Smith A, Nelson L, Torgerson D. Cost-effectiveness analysis of open colposuspension versus laparoscopic colposuspension in the treatment of urodynamic stress incontinence. BJOG 2006;113:1014–22. 10.1111/j.1471-0528.2006.01036.x. [PubMed: 16956333] [CrossRef]
178.
Jacklin P, Duckett J, Renganathan A. Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence. Int Urogynecol J 2010;21:977–84. 10.1007/s00192-010-1132-2. [PubMed: 20349177] [CrossRef]
179.
Kilonzo M, Vale L, Stearns SC, Grant A, Cody J, Glazener C, et al. Cost effectiveness of tension-free vaginal tape for the surgical management of female stress incontinence. Int J Technol Assess Health Care 2004;20:455–63. 10.1017/S0266462304001357. [PubMed: 15609795] [CrossRef]
180.
Manca A, Sculpher MJ, Ward K, Hilton P. A cost–utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG 2003;110:255–62. [PubMed: 12628263]
181.
Mihaylova B, Pitman R, Tincello D, Van Der Vaart H, Tunn R, Timlin L, et al. Cost-effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) study. Value Health 2010;13:565–72. 10.1111/j.1524-4733.2010.00729.x. [PubMed: 20456715] [CrossRef]
182.
Wu JM, Visco AG, Weidner AC, Myers ER. Is Burch colposuspension ever cost-effective compared with tension-free vaginal tape for stress incontinence? Am J Obstet Gynecol 2007;197:62.e1–5. 10.1016/j.ajog.2007.02.039. [PubMed: 17618760] [CrossRef]
183.
Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Value Health 2011;14:219–28. 10.1016/j.jval.2010.08.006. [PubMed: 21402292] [CrossRef]
184.
Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 2011;108:558–64. 10.1111/j.1464-410X.2010.09905.x. [PubMed: 21166750] [CrossRef]
185.
Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 2009;182:2799–804. 10.1016/j.juro.2009.08.031. [PubMed: 19837427] [CrossRef]
186.
Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol 2009;181:2181–6. 10.1016/j.juro.2009.01.037. [PubMed: 19296983] [CrossRef]
187.
Schultz SE, Kopec JA. Impact of chronic conditions. Health Rep 2003;14:41–53. [PubMed: 14608795]
188.
Subak LL, Brubaker L, Chai TC, Creasman JM, Diokno AC, Goode PS, et al. High costs of urinary incontinence among women electing surgery to treat stress incontinence. Obstet Gynecol 2008;111:899–907. 10.1097/AOG.0b013e31816a1e12. [PMC free article: PMC2593129] [PubMed: 18378749] [CrossRef]
189.
NICE. Guide to the Methods of Technology Appraisal. London: NICE; 2013.
190.
Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009;13(29). 10.3310/hta13290. [PubMed: 19500484] [CrossRef]
191.
Briggs AH, Claxton K, Sculpher MJ. Decision Modelling For Health Economic Evaluation. Oxford: Oxford University Press; 2006.
192.
NICE. Social Value Judgements: Principles for the Development of NICE Guidance. 2nd edn. London: NICE; 2008. [PubMed: 27905706]
193.
Clark AL, Gregory T, Smith VJ, Edwards R. Epidemiologic evaluation of reoperation for surgically treated pelvic organ prolapse and urinary incontinence. Am J Obstet Gynecol 2003;189:1261–7. 10.1067/S0002-9378(03)00829-9. [PubMed: 14634551] [CrossRef]
194.
Radley SC, Rosario DJ, Chapple CR, Farkas AG. Conventional and ambulatory urodynamic findings in women with symptoms suggestive of bladder overactivity. J Urol 2001;166:2253–8. 10.1016/S0022-5347(05)65545-0. [PubMed: 11696746] [CrossRef]
195.
Dokmeci F, Seval M, Gok H. Comparison of ambulatory versus conventional urodynamics in females with urinary incontinence. Neurourol Urodyn 2010;29:518–21. 10.1002/nau.20821. [PubMed: 19731314] [CrossRef]
196.
Gorton E, Stanton S. Ambulatory urodynamics: do they help clinical management? BJOG 2000;107:316–9. 10.1111/j.1471-0528.2000.tb13224.x. [PubMed: 10740325] [CrossRef]
197.
Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011;30:556–62. 10.1002/nau.21021. [PubMed: 21351127] [CrossRef]
198.
Bump RC, Norton PA, Zinner NR, Yalcin I, Group DUIS. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol 2003;102:76–83. 10.1016/S0029-7844(03)00376-4. [PubMed: 12850610] [CrossRef]
199.
Gray A, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of Cost-Effectiveness Analysis in Healthcare. Oxford: Oxford University Press; 2010.
200.
Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D Utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value Health 2013;16:394–402. 10.1016/j.jval.2012.12.005. [PubMed: 23538192] [CrossRef]
201.
Coast J, Flynn TN, Natarajan L, Sproston K, Lewis J, Louviere JJ, et al. Valuing the ICECAP capability index for older people. Soc Sci Med 2008;67:874–82. 10.1016/j.socscimed.2008.05.015. [PubMed: 18572295] [CrossRef]
202.
203.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760–6. 10.1046/j.1464-410x.2001.02228.x. [PubMed: 11412210] [CrossRef]
204.
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327–36. [PubMed: 12811491]
205.
Thuroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, et al. [EAU guidelines on urinary incontinence.] Actas Urol Esp 2011;35:373–88. 10.1016/j.acuroe.2011.03.002. [PubMed: 21600674] [CrossRef]
206.
Farrell SA, Epp A, Flood C, Lajoie F, MacMillan B, Mainprize T, et al. The evaluation of stress incontinence prior to primary surgery. J Obstet Gynaecol Can 2003;25:313–24. [PubMed: 12679823]
207.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem Lab Med 2003;41:68–73. 10.1515/CCLM.2003.012. [PubMed: 12636052] [CrossRef]
208.
Ogunyemi TO, Siadat MR, Arslanturk S, Killinger KA, Diokno AC. Novel application of statistical methods to identify new urinary incontinence risk factors. Adv Urol 2012;2012:276501. 10.1155/2012/276501. [PMC free article: PMC3501817] [PubMed: 23193394] [CrossRef]
209.
Frenkl TL, Railkar R, Palcza J, Scott BB, Alon A, Green S, et al. Variability of urodynamic parameters in patients with overactive bladder. Neurourol Urodyn 2011;30:1565–9. 10.1002/nau.21081. [PubMed: 21674594] [CrossRef]
210.
Grant AM, Altman DG, Babiker AG, Campbell MK, Clemens F, Darbyshire JH, et al. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005;365:711–22. 10.1016/S0140-6736(05)70939-9. [PubMed: 15721478] [CrossRef]
211.
Medical Research Council. MRC Guidelines for Good Clinical Practice for Clinical Trials. London: Medical Research Council; 1998.
212.
Daniels J, Gray J, Pattison H, Roberts T, Edwards E, Milner P. Rapid testing for group B streptococcus during labour: a test accuracy study with evaluation of acceptability and cost-effectiveness. Health Technol Assess 2009;13(42). 10.3310/hta13420. [PubMed: 19778493] [CrossRef]
213.
Macskassy SA, Provost F, Rosset S, editors. ROC Confidence Bands: An Empirical Evaluation. Proceedings of the 22nd international conference on Machine Learning. Bonn: Association for Computing Machinery; 2005. 10.1145/1102351.1102419. [CrossRef]
214.
Pannek J, Bartel P, Gocking K, Frotzler A. Clinical usefulness of ultrasound assessment of detrusor wall thickness in patients with neurogenic lower urinary tract dysfunction due to spinal cord injury: urodynamics made easy? World J Urol 2013;31:659–64. 10.1007/s00345-012-0970-6. [PubMed: 23073657] [CrossRef]
Copyright © Queen’s Printer and Controller of HMSO 2016. This work was produced by Rachaneni et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK338659
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (15M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...